[ad_1]
The company now claims that the vaccine is 76% effective in preventing any case of COVID-19, up from 79% as previously announced.
It is true that the vaccine is still 100 percent. protects against severe cases of the disease.
AstraZeneca reported slightly lower efficacy after a panel of independent experts overseeing vaccine trials expressed concern that AstraZeneca had not included updated data in its calculation of vaccine efficacy.
The US National Institutes of Health issued a report urging AstraZeneca to work with a panel of experts to update the data.
“We look forward to ordering an emergency vaccine in the United States and preparing to use millions of doses in the Americas,” said Mene Pangalos, vice president of pharmaceutical research and development for AstraZeneca.
The updated vaccine efficacy data is based on 190 people who developed COVID-19 out of 32,449 study participants in the United States, Peru, and Chile. Of all the people in the studies, two-thirds received the vaccine and one-third received placebo.
The previous measure of vaccine effectiveness was published based on 141 COVID-19 cases, as cases registered after mid-February were not included.
AstraZeneca added that 14 other possible COVID-19 cases are currently being investigated.
Years of research of more than 32 thousand. only 8 people developed severe COVID-19 disease, but all received placebo instead of the actual vaccine.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
